Endovascular Diagnosis of Pulmonary Artery Intimal Sarcoma Using Intracardiac Echocardiography–Guided Biopsy Authors: Christoph Matthias, Christiane Wiedemann, Hanna Waldsperger, Felix K.F. Kommoss, Philipp Schlegel, Matthias Eden, Nicolas Geis, Florian André, Haitham Abu Sharar, Lorenz Lehmann, Norbert Frey, Mathias Konstandin, Benjamin Meder, Janek Salatzki Published: 2026 ABSTRACT BackgroundPrimary tumors of the pulmonary artery are rare and often mimic thromboembolic disease, leading to delayed diagnosis with potentially serious consequences.Case SummaryA middle-aged woman with reduced exercise tolerance was found to have a progressive left hilar mass causing near-complete obstruction of the left pulmonary artery. Given high procedural risk, an intracardiac echocardiography (ICE)–guided endovascular biopsy was performed. Tissue sampling was successful and complication free. Histopathology and molecular analysis demonstrated a malignant pleomorphic neoplasm with MDM2 amplification, consistent with pulmonary artery intimal sarcoma.DiscussionICE-guided biopsy enables safe, real-time tissue acquisition from central pulmonary artery lesions. This technique enables timely histological and molecular diagnosis, especially when conventional biopsy approaches are deemed too risky.Take-Home MessagesPulmonary artery intimal sarcoma should be differentiated from thromboembolic disease using imaging and clinical progression. ICE-guided biopsy represents a safe diagnostic option in high-risk cases and supports multidisciplinary decision-making. Visual SummaryICE-Guided Endovascular Diagnosis of Pulmonary Artery Intimal SarcomaA patient with progressive dyspnea despite anticoagulation for presumed pulmonary embolism showed imaging features atypical for thromboembolic disease. Given high procedural risk, intracardiac echocardiography (ICE)–guided endovascular biopsy was used to enable safe, real-time, targeted tissue acquisition. Histopathology confirmed pulmonary artery intimal sarcoma with MDM2 amplification, guiding multidisciplinary management. ICE-guided biopsy represents a minimally invasive diagnostic alternative for high-risk pulmonary artery lesions. The Visual Summary was created with the assistance of an artificial intelligence–based tool (ChatGPT, OpenAI) for conceptual layout and wording. The authors take full responsibility for the accuracy, originality, and integrity of the content. FDG = 18F-fluorodeoxyglucose; PET-CT = positron emission tomography–computed tomography. ICE-Guided Endovascular Diagnosis of Pulmonary Artery Intimal Sarcoma A patient with progressive dyspnea despite anticoagulation for presumed pulmonary embolism showed imaging features atypical for thromboembolic disease. Given high procedural risk, intracardiac echocardiography (ICE)–guided endovascular biopsy was used to enable safe, real-time, targeted tissue acquisition. Histopathology confirmed pulmonary artery intimal sarcoma with MDM2 amplification, guiding multidisciplinary management. ICE-guided biopsy represents a minimally invasive diagnostic alternative for high-risk pulmonary artery lesions. The Visual Summary was created with the assistance of an artificial intelligence–based tool (ChatGPT, OpenAI) for conceptual layout and wording. The authors take full responsibility for the accuracy, originality, and integrity of the content. FDG = 18F-fluorodeoxyglucose; PET-CT = positron emission tomography–computed tomography. History of Presentation A middle-aged woman presented with progressive exertional dyspnea over several weeks. One month earlier, she had been hospitalized with multiple central and peripheral pulmonary emboli and was discharged on therapeutic anticoagulation. Since discharge, her dyspnea gradually worsened without acute deterioration.Take-Home Messages•Pulmonary artery intimal sarcoma should be differentiated from thromboembolic disease using imaging and monitoring of clinical progression.•Intracardiac echocardiography–guided biopsy represents a safe diagnostic option in high-risk pulmonary artery lesions.•Multidisciplinary decision-making is essential in rare pulmonary vascular tumors beyond guideline recommendations. Take-Home Messages •Pulmonary artery intimal sarcoma should be differentiated from thromboembolic disease using imaging and monitoring of clinical progression.•Intracardiac echocardiography–guided biopsy represents a safe diagnostic option in high-risk pulmonary artery lesions.•Multidisciplinary decision-making is essential in rare pulmonary vascular tumors beyond guideline recommendations. •Pulmonary artery intimal sarcoma should be differentiated from thromboembolic disease using imaging and monitoring of clinical progression. Pulmonary artery intimal sarcoma should be differentiated from thromboembolic disease using imaging and monitoring of clinical progression. •Intracardiac echocardiography–guided biopsy represents a safe diagnostic option in high-risk pulmonary artery lesions. Intracardiac echocardiography–guided biopsy represents a safe diagnostic option in high-risk pulmonary artery lesions. •Multidisciplinary decision-making is essential in rare pulmonary vascular tumors beyond guideline recommendations. Multidisciplinary decision-making is essential in rare pulmonary vascular tumors beyond guideline recommendations. She denied chest pain, syncope, palpitations, orthopnea, fever, or hemoptysis. Her body weight was stable, and her vital signs were stable on physical examination. There were no clinical signs suggestive of recurrent acute pulmonary embolism. Cardiopulmonary examination was unremarkable, without signs of right heart failure or peripheral edema. Functional capacity was limited, partly because of pre-existing multiple sclerosis with left-sided lower limb impairment. Past Medical History The patient had a history of left-sided invasive ductal breast cancer treated with breast-conserving surgery, sentinel lymph node biopsy, and adjuvant radiotherapy. She was receiving tamoxifen. Additional comorbidities included relapsing-remitting multiple sclerosis and arterial hypertension. There was no known history of venous thromboembolism prior to the recent event. The patient was married and lived with her husband. She worked in an office-based occupation and reported no occupational exposure to hazardous substances. Her family history included breast cancer in her mother and lung cancer on the paternal side. She reported seasonal allergic rhinitis. She was a lifelong nonsmoker and consumed alcohol occasionally. Differential Diagnosis Chronic thromboembolic pulmonary disease was initially considered most likely. However, contrast-enhanced computed tomography (CT) demonstrated progressive intraluminal growth with extraluminal extension beyond the pulmonary artery wall. These findings were atypical for organized thrombus. Malignant etiologies were prioritized, particularly pulmonary artery intimal sarcoma and pulmonary artery angiosarcoma. Tumor embolism from an extrathoracic malignancy, including breast cancer recurrence, was considered. Large-vessel vasculitis was deemed less likely given the imaging characteristics and clinical context. Investigations Laboratory testing showed elevated inflammatory markers, normocytic anemia, and increased fibrinogen levels. Renal function and cardiac biomarkers were normal. Tumor markers were within reference ranges (Table 1).Table 1Results of Laboratory TestingValueReference RangeC-reactive protein13.0 mg/L<5.0 mg/LHemoglobin9.6 g/dL12.0-15.0 g/dLHematocrit0.2990.36-0.47Erythrocytes3.34 × 106/μL4.4-5.2 × 106/μLLeukocytes5.6 × 103/μL4.0-10.0 × 103/μLPlatelets394 × 103/μL150-440 × 103/μLFibrinogen (Clauss)4.67 g/L1.8-3.5 g/LINR1.01<1.2Creatinine0.60 mg/dL0.5-1.1 mg/dLeGFR (CKD-EPI)92 mL/min/1.73 m2>60 mL/min/1.73 m2AST44 U/L<37 U/LALT112 U/L<35 U/LLDH292 U/L<301 U/LAlbumin34.8 g/L30-50 g/LCEA<0.5 μg/L<2.5 μg/LALT = alanine aminotransferase; AST = aspartate aminotransferase; CEA = carcinoembryonic antigen; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; eGFR = estimated glomerular filtration rate; INR = international normalized ratio; LDH = lactate dehydrogenase. Table 1Results of Laboratory TestingValueReference RangeC-reactive protein13.0 mg/L<5.0 mg/LHemoglobin9.6 g/dL12.0-15.0 g/dLHematocrit0.2990.36-0.47Erythrocytes3.34 × 106/μL4.4-5.2 × 106/μLLeukocytes5.6 × 103/μL4.0-10.0 × 103/μLPlatelets394 × 103/μL150-440 × 103/μLFibrinogen (Clauss)4.67 g/L1.8-3.5 g/LINR1.01<1.2Creatinine0.60 mg/dL0.5-1.1 mg/dLeGFR (CKD-EPI)92 mL/min/1.73 m2>60 mL/min/1.73 m2AST44 U/L<37 U/LALT112 U/L<35 U/LLDH292 U/L<301 U/LAlbumin34.8 g/L30-50 g/LCEA<0.5 μg/L<2.5 μg/LALT = alanine aminotransferase; AST = aspartate aminotransferase; CEA = carcinoembryonic antigen; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; eGFR = estimated glomerular filtration rate; INR = international normalized ratio; LDH = lactate dehydrogenase. Results of Laboratory Testing ALT = alanine aminotransferase; AST = aspartate aminotransferase; CEA = carcinoembryonic antigen; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; eGFR = estimated glomerular filtration rate; INR = international normalized ratio; LDH = lactate dehydrogenase. Electrocardiography demonstrated normal sinus rhythm without signs of right heart dysfunction. Chest x-ray revealed a left hilar opacity (Figure 1A). Contrast-enhanced CT showed a left hilar mass with intraluminal growth into the pulmonary artery trunk and near-subtotal obstruction of the left pulmonary artery. Extraluminal infiltration and persistent perfusion defects despite anticoagulation strongly suggested malignancy (Figure 1B).Figure 1Multimodality Imaging of Pulmonary Artery Intimal Sarcoma(A) Posteroanterior chest x-ray demonstrating a left-sided hilar opacity (arrow), without evidence of pneumothorax, pleural effusion, or acute parenchymal infiltrates. (B) Contrast-enhanced computed tomography axial view showing an intraluminal mass within the left pulmonary artery (LPA; arrow), causing near-subtotal obstruction. The anatomical relationship to the aorta and LPA is illustrated. (C) FDG PET/CT maximum intensity projection revealing intense metabolic activity of the left hilar lesion (arrow), consistent with a metabolically active malignant process, without distant metastatic uptake. (D) Contrast-enhanced thoracic magnetic resonance imaging demonstrating a solid mass compatible with tumor extension involving the pulmonary artery (arrow). FDG = 18F-fluorodeoxyglucose; LA = left atrium; LV = left ventricle; PET/CT = positron emission tomography/computed tomography. Multimodality Imaging of Pulmonary Artery Intimal Sarcoma (A) Posteroanterior chest x-ray demonstrating a left-sided hilar opacity (arrow), without evidence of pneumothorax, pleural effusion, or acute parenchymal infiltrates. (B) Contrast-enhanced computed tomography axial view showing an intraluminal mass within the left pulmonary artery (LPA; arrow), causing near-subtotal obstruction. The anatomical relationship to the aorta and LPA is illustrated. (C) FDG PET/CT maximum intensity projection revealing intense metabolic activity of the left hilar lesion (arrow), consistent with a metabolically active malignant process, without distant metastatic uptake. (D) Contrast-enhanced thoracic magnetic resonance imaging demonstrating a solid mass compatible with tumor extension involving the pulmonary artery (arrow). FDG = 18F-fluorodeoxyglucose; LA = left atrium; LV = left ventricle; PET/CT = positron emission tomography/computed tomography. 18F-fluorodeoxyglucose positron emission tomography/CT demonstrated increased metabolic activity within the lesion without distant metastases (Figure 1C). Contrast-enhanced thoracic magnetic resonance imaging confirmed near-complete obstruction of the left pulmonary artery with peripheral contrast enhancement and no evidence of organized thrombus. Residual perfusion was limited to segments 1 and 2 (Figure 1D). Management Although anticoagulation had been initiated for presumed pulmonary embolism, progressive imaging findings raised concern for an alternative diagnosis. CT demonstrated a progressive left hilar mass measuring 6.9 × 6.4 × 3.7 cm with tumor-like morphology, intraluminal growth, and extraluminal extension. In addition, imaging revealed a low-attenuation filling defect occupying the luminal diameter of the proximal pulmonary artery with associated arterial expansion, imaging features that have been described as suggestive of pulmonary artery sarcoma rather than pulmonary embolism.1 The presence of a persistent and progressive perfusion defect despite therapeutic anticoagulation rendered a purely thromboembolic process unlikely and raised strong suspicion for a malignant vascular neoplasm. Given the central intravascular location and high procedural risk associated with surgical resection or percutaneous transthoracic biopsy, a catheter-based transpulmonary biopsy under intracardiac echocardiography (ICE) guidance was performed. Venous access was obtained via the right femoral vein using a double-puncture technique. The procedure was conducted under local anesthesia without general anesthesia. A steerable sheath was advanced under fluoroscopic guidance into the main pulmonary artery. The ICE catheter was positioned in the right atrium and subsequently in the right ventricular outflow tract to enable real-time visualization of the left pulmonary artery and intraluminal mass. Selective pulmonary angiography demonstrated an abrupt perfusion defect of the left pulmonary artery (Figure 2A). Biopsy forceps were advanced through the guiding catheter into the tumor under continuous ICE monitoring, enabling precise targeting while minimizing the risk of vessel wall injury (Figures 2B and 2C). Ten biopsy specimens (2-3 mm each) were obtained.Figure 2ICE-Guided Endovascular Biopsy of a Pulmonary Artery Tumor(A) Fluoroscopic image obtained immediately before biopsy demonstrating the guiding catheter positioned in the pulmonary artery under intracardiac echocardiography (ICE) guidance. Contrast injection reveals an abrupt perfusion defect with absent opacification of the affected vessel segment, consistent with an intraluminal tumor. (B) Fluoroscopic image during ICE-guided right heart catheterization showing the biopsy forceps advanced through the guiding catheter into the pulmonary artery. The forceps are positioned within the nonopacified intraluminal region corresponding to the tumor, enabling targeted tissue acquisition. (C) ICE images demonstrating the intraluminal tumor within the left pulmonary artery (LPA) and real-time visualization of the biopsy forceps in direct contact with the lesion, allowing precise and controlled sampling under continuous imaging guidance. RV = right ventricle. ICE-Guided Endovascular Biopsy of a Pulmonary Artery Tumor (A) Fluoroscopic image obtained immediately before biopsy demonstrating the guiding catheter positioned in the pulmonary artery under intracardiac echocardiography (ICE) guidance. Contrast injection reveals an abrupt perfusion defect with absent opacification of the affected vessel segment, consistent with an intraluminal tumor. (B) Fluoroscopic image during ICE-guided right heart catheterization showing the biopsy forceps advanced through the guiding catheter into the pulmonary artery. The forceps are positioned within the nonopacified intraluminal region corresponding to the tumor, enabling targeted tissue acquisition. (C) ICE images demonstrating the intraluminal tumor within the left pulmonary artery (LPA) and real-time visualization of the biopsy forceps in direct contact with the lesion, allowing precise and controlled sampling under continuous imaging guidance. RV = right ventricle. The total procedural time was 46 minutes (skin-to-skin). Hemodynamics remained stable throughout. Immediate postprocedural angiography, transthoracic echocardiography, and chest radiography excluded vascular perforation, pericardial effusion, relevant bleeding, pneumothorax, or hemothorax. Follow-Up The patient remained hemodynamically stable without procedure-related complications. Histopathology demonstrated a malignant pleomorphic mesenchymal neoplasm composed of spindle and epithelioid cells, and immunohistochemistry and molecular testing revealed MDM2 (murine double minute 2) amplification, confirming pulmonary artery intimal sarcoma (Figure 3). No distant metastases were identified. Follow-up magnetic resonance imaging showed tumor progression with persistent near-subtotal obstruction and peripheral contrast enhancement. There was no cardiac invasion.Figure 3Histological Examination of the Pulmonary Artery Biopsy(A) Malignant pleomorphic mesenchymal neoplasm composed of atypical spindle cells (hematoxylin and eosin staining). (B) Chromogenic in situ hybridization (CISH) demonstrating MDM2 amplification. Findings are consistent with pulmonary artery intimal sarcoma. Histological Examination of the Pulmonary Artery Biopsy (A) Malignant pleomorphic mesenchymal neoplasm composed of atypical spindle cells (hematoxylin and eosin staining). (B) Chromogenic in situ hybridization (CISH) demonstrating MDM2 amplification. Findings are consistent with pulmonary artery intimal sarcoma. The case was discussed in a multidisciplinary tumor board meeting. Given extensive local disease and absence of resectable margins, definitive radiotherapy was recommended. The patient received definitive hypofractionated helical photon intensity–modulated radiotherapy with a total dose of 60 Gy delivered in 20 fractions (3 Gy per fraction). The target volume encompassed the extensive left hilar mass, including the pulmonary artery trunk, as well as perivascular extension into the upper mediastinum and the pleural extensions. After 4 fractions, treatment had to be interrupted owing to an acute and clinically significant tumor-related hemorrhage presenting with hemoptysis and dyspnea, necessitating short-term intensive care management. After hemodynamic stabilization and cessation of bleeding, radiotherapy was safely resumed and completed as planned without further interruption. No recurrent bleeding events occurred during the remainder of treatment. After completion of radiotherapy, the patient was clinically stable and could be discharged to her home for outpatient follow-up. Discussion Pulmonary artery intimal sarcoma is an ultra-rare malignant vascular tumor, with fewer than 500 cases described worldwide.2,3 These tumors are often not directly addressed in current international cardiology or oncology guidelines.4 In routine clinical practice, patients presenting with central pulmonary artery obstruction are primarily evaluated for thromboembolic disease, in line with guideline-recommended diagnostic algorithms for suspected pulmonary embolism and chronic thromboembolic pulmonary hypertension.5 However, progressive intraluminal lesions despite therapeutic anticoagulation and with imaging features atypical for acute pulmonary embolism should prompt consideration of alternative diagnoses, including malignant vascular tumors. Current guidelines do not provide recommendations for tissue acquisition in suspected pulmonary artery malignancies.3 Establishing histological and molecular diagnosis was considered essential, as therapeutic strategies differ substantially between thromboembolic disease, primary pulmonary malignancy, and intimal sarcoma, including the potential use of sarcoma-specific systemic therapies. Surgical biopsy or resection is often considered the diagnostic standard but may carry prohibitive risk, particularly in centrally located lesions or in patients with relevant comorbidities.3,6, 7, 8 Percutaneous transthoracic biopsy is frequently not feasible because of anatomical constraints and bleeding risk. In this context, the use of ICE to guide endovascular biopsy represents an individualized, multidisciplinary approach that extends beyond guideline-directed practice.4,5 ICE enables real-time visualization of vascular anatomy, precise targeting of intraluminal lesions, and immediate assessment for procedure-related complications such as pericardial effusion.9 Although not addressed in current guidelines, ICE-guided biopsy aligns with contemporary principles of patient-centered, risk-adapted decision-making within specialized cardio-oncology and interventional cardiology teams. Furthermore, molecular characterization is increasingly recognized as essential for the definitive diagnosis of pulmonary artery intimal sarcoma.8 While molecular testing is well established in soft tissue sarcoma guidelines, its application to intravascular pulmonary tumors underscores the importance of close interdisciplinary collaboration between cardiology, radiology, pathology, and oncology. Recent studies have shown that molecular alterations such as MDM2 amplification, commonly found in pulmonary artery intimal sarcomas, play a critical role in diagnosis and treatment planning.10,11 This case illustrates how deviation from standard diagnostic pathways, when guided by multidisciplinary expertise and advanced imaging techniques, can enable safe diagnosis of rare but life-threatening conditions that fall outside current guideline frameworks. Conclusions ICE-guided transpulmonary biopsy represents a novel diagnostic option for centrally located pulmonary artery tumors. This approach enables safe tissue acquisition and may facilitate earlier diagnosis of rare but lethal conditions such as pulmonary artery intimal sarcoma. Funding Support and Author Disclosures This work was supported by the German Centre for Cardiovascular Research (DZHK) and the Deutsche Herzstiftung e.V (to Dr Salatzki). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.